Gyre Therapeutics has agreed to acquire Cullgen in a $300 million all-stock transaction, marking a strategic move to expand its pipeline in targeted protein degradation therapies. The deal is expected to enhance Gyre's innovation capacity in the rapidly growing biotech space.
- Gyre Therapeutics to acquire Cullgen in a $300 million all-stock transaction
- Cullgen shareholders will receive Gyre common stock as consideration
- Deal value reflects a premium to Cullgen’s recent market capitalization
- Closing expected in Q2 2026, pending regulatory and closing conditions
- Acquisition expands Gyre’s pipeline in targeted protein degradation therapies
- Cullgen will operate as a subsidiary under Gyre post-merger
Gyre Therapeutics announced a definitive agreement to acquire Cullgen in an all-stock transaction valued at $300 million. The deal positions Gyre to integrate Cullgen’s proprietary protein degradation platform, which focuses on targeting previously undruggable disease pathways. Under the terms, Cullgen shareholders will receive Gyre common stock as consideration, with the exchange ratio determined by a formula based on the average trading price over a 30-day period prior to closing. The acquisition underscores Gyre’s strategy to strengthen its pipeline in precision medicine, particularly in oncology and neurodegenerative diseases. Cullgen’s technology leverages the ubiquitin-proteasome system to selectively degrade disease-causing proteins, a field that has gained significant traction among biopharma companies in recent years. The $300 million valuation reflects a premium to Cullgen’s recent market capitalization and signals investor confidence in the company’s platform capabilities. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory review. Post-merger, Cullgen will operate as a wholly owned subsidiary of Gyre, with its leadership team continuing to manage the platform’s development. Analysts note that the combination could accelerate the clinical development of novel therapeutics, particularly in solid tumors and protein aggregation disorders. The deal is likely to impact market sentiment for both companies, with potential ripple effects in the broader biotech sector. Investors are watching for indications of how the integration will affect R&D efficiency and future product commercialization timelines.